---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Jul 30, 2008 at 9:30 PM
Subject: Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
To: mesothelioma77@gmail.com
[1]Cancer. 2008 Jul 25;
Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Köstler WJ, Lotz JP, Luftner D, Pichon MF, Lipton A,
BACKGROUND.: Previous reports based on small patient numbers suggested that changes in serum HER-2/neu levels may predict response or lack of response to trastuzumab-based therapies in metastatic breast cancer (MBC). The objectives of this study were to pool data from 307 patients with MBC from 7 medical institutions to validate that the serum HER-2/neu profile predicts patient resistance to trastuzumab and to establish a clinically relevant cutoff. METHODS.: This was an international, multicenter, retrospective analysis of individual pooled data from 307 patients with MBC who were treated with first-line trastuzumab-based therapy. Serum was collected at baseline and 30 to 120 days after the initiation of trastuzumab therapy. A serum HER-2/neu decrease >/=20% (receiver operating curve analysis) was defined as a significant HER-2/neu change. RESULTS.: Of the 307 patients with MBC, 191 patients (62%) had a significant decline (>20%) in serum HER-2/neu and 116 patients (38%) did not. The objective response rate was 57% for patients who achieved this decline in serum HER-2/neu (>20%) compared with 28% for patients who did not. Patients who achieved this decline in serum HER-2/neu also had a significantly longer time to disease progression (320 days vs 180 days; P /=20%) in serum HER-2/neu levels had decreased benefit from trastuzumab-based therapy, and these patients should be considered for clinical trials evaluating additional HER-2/neu-targeted interventions. Cancer 2008. (c) 2008 American Cancer Society.
___
Source: http://www.hubmed.org/display.cgi?uids=18661530
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Jul 30, 2008 at 9:30 PM
Subject: Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
To: mesothelioma77@gmail.com
[1]Cancer. 2008 Jul 25;
Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Köstler WJ, Lotz JP, Luftner D, Pichon MF, Lipton A,
BACKGROUND.: Previous reports based on small patient numbers suggested that changes in serum HER-2/neu levels may predict response or lack of response to trastuzumab-based therapies in metastatic breast cancer (MBC). The objectives of this study were to pool data from 307 patients with MBC from 7 medical institutions to validate that the serum HER-2/neu profile predicts patient resistance to trastuzumab and to establish a clinically relevant cutoff. METHODS.: This was an international, multicenter, retrospective analysis of individual pooled data from 307 patients with MBC who were treated with first-line trastuzumab-based therapy. Serum was collected at baseline and 30 to 120 days after the initiation of trastuzumab therapy. A serum HER-2/neu decrease >/=20% (receiver operating curve analysis) was defined as a significant HER-2/neu change. RESULTS.: Of the 307 patients with MBC, 191 patients (62%) had a significant decline (>20%) in serum HER-2/neu and 116 patients (38%) did not. The objective response rate was 57% for patients who achieved this decline in serum HER-2/neu (>20%) compared with 28% for patients who did not. Patients who achieved this decline in serum HER-2/neu also had a significantly longer time to disease progression (320 days vs 180 days; P /=20%) in serum HER-2/neu levels had decreased benefit from trastuzumab-based therapy, and these patients should be considered for clinical trials evaluating additional HER-2/neu-targeted interventions. Cancer 2008. (c) 2008 American Cancer Society.
___
Source: http://www.hubmed.org/display.cgi?uids=18661530
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc